![](/images/2013/post-sep.jpg)
Gastric Cancer Market Updates 2024 : to Reach USD 10.7 Billion by 2031 : Emerging Therapies and Strategic Analysis
![According to a new report published by Allied Market Research, titled, โGastric Cancer Market," The gastric cancer market size was valued at $2 Gastric Cancer Market - Infographics - AMR](https://img.einnews.com/ampsize/464974/gastric-cancer-market.png)
Gastric Cancer Market - Infographics - AMR
The gastric cancer market was valued at $2.1 billion in 2021, and is estimated to reach $10.7 billion by 2031, growing at a CAGR of 17.9% from 2022 to 2031.
WILMINGTON, DELAWARE , UNITED STATES, July 24, 2024 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, โGastric Cancer Market," The gastric cancer market size was valued at $2.1 billion in 2021, and is estimated to reach $10.7 billion by 2031, growing at a CAGR of 17.9% from 2022 to 2031, fueled by innovative treatment advancements and strategic industry initiatives. A newly published report offers an in-depth analysis of emerging therapies and the strategic dynamics reshaping the future of gastric cancer care.
As gastric cancer remains one of the leading causes of cancer-related mortality worldwide, significant efforts in research and development have led to groundbreaking therapeutic advancements. New targeted therapies, immunotherapies, and personalized medicine approaches are transforming patient outcomes and setting new standards in gastric cancer treatment.
By treatment type, the chemotherapy segment captured nearly half of the global gastric cancer market revenue and is expected to maintain its dominance by 2031. Conversely, the targeted therapy segment is projected to achieve the fastest compound annual growth rate (CAGR) of 19.2% during the forecast period. The report also examines the immunotherapy, radiation therapy, and surgery segments.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/A74458
By drug class outlook, the PD-1/PD-L1 inhibitors segment is forecasted to exhibit the fastest CAGR of 18.7% throughout the forecast period. The report also analyzes the HER2 antagonists, VEGFR2 antagonists, and other segments.
By distribution channel, the specialty and retail pharmacies segment accounted for nearly three-fifths of the global gastric cancer market revenue and is anticipated to retain its leading position by 2031. This segment is also expected to register the fastest CAGR of 18.5% over the forecast period. Additionally, the report evaluates the hospital pharmacies and other segments.
๐๐๐ฒ ๐
๐ข๐ง๐๐ข๐ง๐ ๐ฌ ๐จ๐ ๐ญ๐ก๐ ๐๐ญ๐ฎ๐๐ฒ
Based on disease type, the adenocarcinoma sub-segment emerged as the global leader in 2021 and is anticipated to be the fastest growing during the gastric cancer market forecast period
Based on treatment type, the chemotherapy sub-segment emerged as the global leader in 2021 and the targeted therapy sub-segment is predicted to show the fastest growth in the upcoming years
Based on drug class outlook, the PD-1/PD-L1 inhibitors sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
Based on route of administration, the oral sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
Based on distribution channel, the specialty & retail pharmacies sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
Based on region, the Asia-Pacific market registered the highest gastric cancer market share in 2021 and is projected to maintain its position during the forecast period.
๐๐๐ฒ ๐๐๐ง๐๐๐ข๐ญ๐ฌ ๐
๐จ๐ซ ๐๐ญ๐๐ค๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌ
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer market analysis from 2021 to 2031 to identify the prevailing gastric cancer market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gastric cancer market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gastric cancer market trends, key players, market segments, application areas, and market growth strategies.
๐๐๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ
Samsung Bioepis
Celltrion Healthcare Co., Ltd.
Eli Lilly & Company
Merck & Co., Inc.
Bristol Myers Squibb Company
Mylan N.V.
Novartis AG
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
F. Hoffmann La Roche Ltd.
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐๐ข๐๐ ๐๐๐ข๐๐ง๐๐ ๐๐จ๐ฆ๐๐ข๐ง
๐๐ฎ๐ฆ๐จ๐ซ ๐๐๐ฅ๐๐ญ๐ข๐จ๐ง ๐ฆ๐๐ซ๐ค๐๐ญ https://www.alliedmarketresearch.com/tumor-ablation-market-A17208
๐๐ข๐๐จ๐ญ๐ข๐ง๐ ๐๐๐ฉ๐ฅ๐๐๐๐ฆ๐๐ง๐ญ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐๐ซ๐ค๐๐ญ https://www.alliedmarketresearch.com/nicotine-replacement-therapy-market-A31526
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X
![](https://corporategovernance.einnews.com/tracking/article.gif?aid=730034076§ion=einpresswire&a=sJPlKOB5kOw92hZV&i=eN4lnTAFGvsSRH0P)
Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release